Jazz Pharmaceuticals (JAZZ) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $230.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Samimy covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Ligand Pharma, and Jazz Pharmaceuticals. According to TipRanks, Samimy has an average return of 17.0% and a 50.59% success rate on recommended stocks.
In a report released yesterday, Needham also maintained a Buy rating on the stock with a $210.00 price target.
Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.13 billion and a net profit of $251.41 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $215.06 million
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Last month, Mary Elizabeth Henderson, the SVP Tech. Op of JAZZ sold 2,238.00 shares for a total of $379,363.38.
Read More on JAZZ:
Disclaimer & DisclosureReport an Issue
- Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS
- Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial
- Jazz reports efficacy, safety results from Phase 3 HERIZON-GEA-01 trial
- Jazz Pharmaceuticals Completes Observational Study on Vyxeos Liposomal in AML Treatment
